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PHARMACY
Impact of Pharmacist-lead Antibiotic 
Stewardship Program in a Pediatric Intensive 
Care Unit (PICU)
Kashif Hussain, Specialist, Pharmacy Services 
Antibiotic Stewardship Program (ASP) has improved the utilization of 
antibiotics in hospitalized patients. We prospectively conducted a pilot project of 
pharmacist-lead ASP, with audit and feedback, in a closed multidisciplinary PICU 
and compared with historical control in utilization of antibiotics for 3 months. 
The team of ASP is composed of Pharmacist who has expertise in ASP, pediatric 
intensives and pediatric infectious disease consultants. Antibiotic exposure on 
daily basis is considered as Day of Therapy (DOT). 135 and 127 patients were in 
control and intervention group respectively. Patient’s characteristics were same 
in both groups. DOT in control and intervention groups were 1937 & 1074 per 
1000 patient days and 651 & 320 per1000 patient days respectively (p<0.001). 
Similar reduction was noted in individual antibiotic except Colistin. Antibiotics 
were stopped after 2 days in 8 patients in control group versus 57 patients in 
intervention group. 29 (22.6%) pharmacist intervention were recorded; including 
dose adjustment (11), selection of antibiotics (15), dose de-escalation (5) and 
monitoring recommendation (6).
Duration alerts by pharmacist were not included in it. There was about >50% 
cost saving in ASP period (PKR 2212468/= vs. 92568/=; p<0.001). There was 
no difference in mortality between two groups. Pharmacist-lead ASP in a PICU 
have a significant impact on decreasing use of antibiotics as well as cost-reducing 
intervention.
References:
	 l	 De Waele JJ, Schouten J, Dimopoulos G. Understanding antibiotic stewardship 
  for the critically ill. Intensive Care Med. 2016;42:2063-5.
	 l Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, 
  et al. Implementing an Antibiotic Stewardship Program: Guidelines by the 
  Infectious Diseases Society of America and the Society for Healthcare 
  Epidemiology of America. Clin Infect Dis. 2016; 62:e51-77.
Twice Daily Dose of Levetiracetam and 
Clinical Pharmacokinetics
Mohd Amir, Specialist, Pharmacy Services 
Levetiracetam is a second-generation, anti-epileptic drug, which is commonly 
used as a mono- or adjunctive therapy for treating patients with partial and 
generalized epilepsy. It is a highly soluble drug with high volume of distribution 
(0.7L/kg) and half-life of 07 hours. The dosing regimen recommended is twice 
daily. Due to its high volume of distribution, twice daily dosing regimen allows 
steady state concentration to be achieved in two days. Furthermore, however, 
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10% Calcium Gluconate
IV Dextrose and Insulin
Salbutamol
Sodium bicarbonate                                                                   
Correction of an existing metabolic 
acidosis can be considered
Polystyrene Sodium Sulfonate (should 
be avoided in preterm infants)
• 0.5 ml/kg IV over 10-30 min. The dose of calcium gluconate may be repeated.
• Dextrose: 3-4 ml/kg/hr 25% dextrose in addition to maintenance fluid, aim for 
 blood glucose concentration (BGC) > 12 mmol/l. When BGC >12 mmol/L, start 
 insulin infusion (0.1-0.6 units/kg/hr).
• Nebulize: 400 micrograms/dose (made up to a total of 4 ml with normal saline) 
 up to 2 hrly. 
• Sodium bicarbonate dose (ml) = base deficit x 0.6 x weight (kg).
• 0.5 – 1 g/kg rectally
Treatment Strategies Doses
Table 01:  Treatment Strategies of Acute Hyperkalemia in Neonates
References:
	 l	 Vemgal P, Ohlsson A. Interventions for non-oliguric hyperkalaemia in preterm neonates. Cochrane database Syst Rev.  
  2012;5:CD005257.
	 l Hu PS, Su BH, Peng CT, Tsai CH. Glucose and insulin infusion versus kayexalate for the early treatment of non-oliguric  
  hyperkalemia in very-low-birth-weight infants. Acta Paediatr Taiwan;40:314–8.
	 l	 Singh	BS,	Sadiq	HF,	Noguchi	A,	Keenan	WJ.	Efficacy	of	albuterol	inhalation	in	treatment	of	hyperkalemia	in	premature		
  neonates. J Pediatr. 2002 ;141:16–20.
Influenza Oral Tablet Vaccine Shows Promise in Phase 2 Trial
Hafsah M. Ashfaq- Clinical Pharmacist
A tablet vaccine for flu could significantly change the way we administer vaccines,”
An investigational H1 influenza oral tablet vaccine was found to provide comparable defense against influenza as an 
injectable quadrivalent influenza vaccine (QIV) in a Phase 2 clinical trial. 
The study results showed that the tablet vaccine has a good safety profile and it has provided a 39% reduction in clinical 
disease relative to placebo, compared to a 27% reduction with injectable QIV.
throughout the clinical trials evaluation program of Levetiracetam, a highly efficacious and sustainable effect was 
observed with twice daily administration and indeed this is now the clinically practiced strategy.
Preferable Route of Administration: Oral product has 100 % bioavailability however, it may interact with food resulting 
in reduction of 20% of maximum concentration and delay in time for peak by 1.5 hours. Cost effective value of oral is 
much better than IV.
References:
	 l	 Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinetic. 2004; 43(11):707-24.
	 l Product Information: KEPPRA(R) oral tablets, solution, levetiracetam oral tablets, solution. UCB Inc., Smyrna, GA, 2008.
Management of Acute Hyperkalemia in Neonates
Gul Ambreen, Senior Pharmacist
Hyperkalemia is defined as a serum potassium concentration greater than 5.2 mmol/L   (as far as neonate is 
asymptomatic). Complications of hyperkalemia include ECG changes (peaked T waves, broad QRS complexes, and 
arrhythmias), ventricular tachycardia and impaired AV conduction. Hyperkalemia in the NICU is most commonly 
associated with non-oliguric hyperkalemia due to immature function of the erythrocyte Na/K – ATPase, Oliguric renal 
failure and metabolic acidosis.
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Table 02: List of Drug Associated with NMS
References:
	 l Oruch R, Pryme IF, Engelsen BA, Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.  
  Neuropsychiatric disease and treatment. 2017; 13:161.
 l Buckley PF, Hutchinson M. Neuroleptic malignant syndrome. J Neurol Neurosurg Psychiatr. 1995; 58(3):271-273.
Typical 
antipsychotics 
• Chlorpromazine
• Chlorprothixene
• Haloperidol
• Pimozide
• Fluphenazine
• Thioridazine
• Trifluoperazine
Atypical  
antipsychotics 
• Clozapine
• Olanzapine
• Quetiapine
• Resperidone
• Ziprasidone
• Aripiprazole
Antiemetic
• Dropiredol
• Metoclopramide
• Prochlorperazine
• Promethazine
Dopaminergic
 
• Amantidine
• Bromocriptine
• Carbidopa
• Levodopa
• Tolcapone
Others
• Desipramine
• Dosulpine
• Lithium
• Phenelzine
• Reserpine
• Tetrabenazine
• Trimipramine
This oral vaccine is delivered to the epithelium of small intestine where they activate the local immune system of the 
gut, and this in turn generates a broad local and systemic immune response. This vaccine does not enter the bloodstream 
and prevents neutralization by blood or muscle tissue-based immune system. This effective way of administering 
the vaccine in a tablet form will significantly increase the compliance and will provide health benefits for high risk 
population.
Reference:
	 l Influenza	Oral	Tablet	Vaccine	Shows	Promise	in	Phase	2	Trial;	http://www.empr.com/drug	(Accessed	24/11/2017)
Drug Induced Neuroleptic Malignant Syndrome (NMS)
Mahreen Sohail, Trainee Pharmacist
The use of antipsychotic drugs can cause a rare, life-threatening, idiosyncratic condition known as Neuroleptic 
malignant syndrome.  NMS is characterized by hyperthermia, muscles rigidity, dysautonomia and mental status 
changes. NMS mostly occur within 2 weeks of therapeutic initiation. Treatment involves immediate withdrawal of 
causative agent and supportive care, which includes, volume resuscitation, correction of electrolyte abnormalities, 
IV fluids and parenteral nutrition are recommended for patients in respiratory distress or those unable to tolerate oral 
intake. Treatment includes, direct acting skeletal muscles relaxant, centrally acting dopamine agonist (bromocriptine 
and amantadine) and benzodiazepines are reserved for patients who do not respond to withdrawal of medication and 
supportive care. 
Pharmacists play a crucial role in counseling the patient or the caregivers about the possible side effects and measures 
taken in case of emergency, advising physicians on recognition of early symptoms and therapeutic options or 
alternatives in NMS treatment.
Drug-Drug Interaction – QT Interval Prolongation 
Sumaira Khan, Specialist, Pharmacy Services
An elderly woman of 67 years old with history of stroke and diabetes mellitus (DM) was on multiple drugs including 
Fluoxetine and Donepezil. Her heart monitoring showed prolonged QT waves. Pharmacist on clinical rounds identified 
drug –drug interaction between Fluoxetine and Donepezil.  Donepezil has been associated with QT-interval prolonga-
tion. Studies suggest to use caution when administering donepezil concomitantly with other drugs that cause QT-interval 
prolongation like Fluoxetine as it may result in increased risk of QT-interval prolongation and torsade de pointes. Health 
care team agreed with scientific evidence and discontinued the Fluoxetine.
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The Aga Khan University Hospital, Karachi
Provide us your Valuable Feedback!
To keep the Pharmacy Newsletter of Aga Khan University Hospital (AKUH) updated we would like to take your valuable feedback. We are grateful 
to you for sparing few minutes of your precious time to complete form by below online link or form can be emailed to you as well. Just drop us an 
email with subject Newsletter Feedback. Email us at:drug.information@aku.edu 
Thank you in advance for your feedback! 
Link: 
https://goo.gl/forms/Ghh1Nc2KY2jEkiUL2
Reference:
	 l	 Takaya	T,	Okamoto	M,	Yodoi	K	et	al:	Torsades	de	Pointes	with	QT	prolongation	related	to	donepezil	use.	J	Cardiol	Dec,		
  2009; 54(3):507-511.
	 l Tanaka A: Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade  
  de Pointes. Intern Med 2009; 48(14):1219-1223.
Influenza and Influenza Vaccine Myths and Reality
Drug & Poison Information Team
Acknowledge: This table has been accessed on 29th December, 2017, retrieved from 
https://www.jointcommission.org/assets/1/6/JC_influenza_myths.pdf
Myth
•  The flu vaccine can cause  
 influenza.
• The flu shot doesn’t
  work.
• Our staff follows 
 Standard Precautions, 
 with good hand hygiene 
 practices and appropriate 
 glove and mask use – so 
 vaccination is not necessary.
• Our staff stays at home if 
 they are sick - so 
 vaccination is not 
 necessary.
• There is no evidence to  
 support that influenza 
 vaccination of staff im
 proves patient outcomes.
• Influenza vaccinations 
 for staff will be too costly.
Reality
• The injectable flu vaccine does not contain the live virus so it is impossible to get influenza from the vaccine. 
 Side effects may occur in some people, such as mild soreness, redness, or swelling at the injection site, head
 ache, or a low-grade fever. The nasal spray flu vaccine contains live, attenuated (weakened) viruses that can
 cause mild signs or symptoms such as runny nose, fever, sore throat, and nasal congestion. This vaccine, 
 however, cannot cause influenza infection in the lower respiratory tract. Vaccination is safe and effective, and 
 the best way to help prevent influenza and its complications. 
• The influenza vaccine will prevent influenza most of the time. In scientific studies, the effectiveness of the 
 vaccine ranges from 70 to 90 percent, depending on how well the circulating viruses match those in the 
 vaccine. In populations in which the vaccine is less effective in preventing influenza, such as the elderly, 
 the vaccine reduces the severity of the disease and the incidence of complications by 50 to 60 percent and the 
 incidence of death by approximately 80 percent. Getting vaccinated is the most effective way to protect  
 against influenza and its serious outcomes.
• Influenza is spread by respiratory droplets generated when talking, coughing or sneezing. Adults shed 
 influenza virus at least one day before any signs or symptoms of the disease, so health care personnel can 
 unknowingly infect patients or other staff. 50 percent of influenza infections can be asymptomatic, and both 
 symptomatic and asymptomatic individuals can shed the virus and infect others.
• Since unvaccinated individuals are contagious at least one day before any signs or symptoms of influenza 
 appear, they can still shed the virus and infect patients and other staff. Unvaccinated health care personnel 
 can become infected with influenza and not have any symptoms, and both symptomatic and asymptomatic 
 individuals can shed the virus and infect others.
• Health care personnel can acquire influenza from the community or their patients and can transmit it to 
 patients or other staff. Influenza transmission and outbreaks in health care organizations have been 
 recognized for many years and have been associated with substantial morbidity, mortality, and costs.  
 Influenza’s short incubation period and ease of transmission through respiratory droplets from person 
 to person can result in explosive outbreaks of febrile respiratory illness. Health care settings are favorable 
 environments for such transmission. Increased rates of staff vaccination result in decreased rates of 
 health care-associated influenza.  In fact, one group of researchers concluded that the reduction in morbidity, 
 mortality, and use of health service resources associated with vaccinating their long term care facility was 
 “equivalent to preventing five deaths, two admissions to hospitals with influenza-like illness, seven general 
 practitioner consultations for influenza-like illness, and nine cases of influenza-like illness per 100 residents 
 during the period of influenza activity.”
• The cost savings associated with health care personnel influenza vaccination programs generally outweigh 
 the costs associated with providing the vaccine, and vaccinating ultimately results in a safer environment for 
 patients.
